lenalidomide and Venous Thromboembolism
lenalidomide has been researched along with Venous Thromboembolism in 35 studies
Research
Studies (35)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (11.43) | 29.6817 |
2010's | 22 (62.86) | 24.3611 |
2020's | 9 (25.71) | 2.80 |
Authors
Authors | Studies |
---|---|
Baljevic, M; Callander, NS; Castillo, JJ; Hillengass, J; Kumar, SK; Lim, MY; Martin, T; Sborov, DW; Streiff, MB | 1 |
Attal, M; Chalayer, E; Collet, P; Frenzel, L; Guyotat, D; Karlin, L; Leleu, X; Talbot, A; Tardy, B | 1 |
Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM | 1 |
Fiala, MA; Kavanaugh, M; Loncharich, AJ; Sanfilippo, KM; Schroeder, MA; Slade, MJ; Stockerl-Goldstein, K; Vickroy, A; Vij, R; Wilson, C | 1 |
Cheng, Q; Hu, Y; Li, J; Li, Q; Sun, C; Xu, A; Yan, H; Zhang, B; Zhao, F | 1 |
Anwer, F; Bin Riaz, I; Chakraborty, R; Khan, SU; Khorana, AA; Kumar, S; Majhail, NS; Malik, SU; Marneni, N; Mejia Garcia, A; Murad, MH; Rajkumar, SV; Wang, Z | 1 |
Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C | 1 |
Derkach, A; Hassoun, H; Hultcrantz, M; Korde, N; Lesokhin, A; Lu, S; Mailankody, S; Orozco, J; Patel, D; Peterson, T; Piedra, K; Shah, U; Tan, C; Wilkins, CR | 1 |
Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S | 1 |
Orna, E; Sancho, JM; Sorigue, M | 1 |
Christos, PJ; Demetres, M; Hammad, H; Leonard, JP; Ruan, J; Yamshon, S | 1 |
Bang, SM; Jo, JC; Kim, JS; Kim, K; Lee, HS; Lee, JJ; Lee, JO; Lee, YJ; Min, CK; Shin, J; Suh, C; Yoon, SS | 1 |
Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C | 1 |
Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M | 1 |
Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U | 1 |
Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV | 1 |
Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S | 1 |
Lentzsch, S; Raza, S; Safyan, RA | 1 |
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
Wiernik, PH | 1 |
Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB | 1 |
Dimopoulos, MA; Fink, L; Finlayson, A; Fu, T; Knight, R; Niesvizky, R; Polavaram, L; Tricot, G; Weber, D; Zangari, M; Zhan, F | 1 |
Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
Mateos, MV | 1 |
Kristinsson, SY | 1 |
Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C | 1 |
González Rodríguez, AP | 1 |
García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E | 1 |
Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB | 1 |
Ay, C; Pabinger, I; Thaler, J | 1 |
Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E | 1 |
Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA | 1 |
Reviews
15 review(s) available for lenalidomide and Venous Thromboembolism
Article | Year |
---|---|
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Topics: Anticoagulants; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboembolism | 2022 |
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Anticoagulants; Dexamethasone; Humans; Incidence; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2020 |
Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Prognosis; Prospective Studies; Venous Thromboembolism | 2018 |
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Venous Thromboembolism | 2018 |
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Postoperative Complications; Thalidomide; Venous Thromboembolism | 2016 |
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Risk; Thalidomide; Venous Thromboembolism | 2016 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism | 2017 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Thrombosis in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism | 2010 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thalidomide; Venous Thromboembolism | 2012 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2008 |
Trials
7 trial(s) available for lenalidomide and Venous Thromboembolism
Article | Year |
---|---|
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Topics: Anticoagulants; Bortezomib; Dexamethasone; gamma-Globulins; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2022 |
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous; Venous Thromboembolism | 2022 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine | 2020 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism | 2019 |
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Female; Fibrin Fibrinogen Degradation Products; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2015 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Enoxaparin; Female; Humans; Incidence; Israel; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation Inhibitors; Pulmonary Embolism; Risk Factors; Thalidomide; Venous Thromboembolism; Venous Thrombosis | 2012 |
Other Studies
13 other study(ies) available for lenalidomide and Venous Thromboembolism
Article | Year |
---|---|
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Venous Thromboembolism | 2023 |
Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Topics: Anticoagulants; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2023 |
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease Management; Disease Susceptibility; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Oligopeptides; Retrospective Studies; Venous Thromboembolism | 2022 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2019 |
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Venous Thromboembolism | 2019 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy.
Topics: Aged; Factor Xa Inhibitors; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Treatment Outcome; Venous Thromboembolism | 2017 |
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Databases, Factual; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Pulmonary Embolism; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration; Venous Thromboembolism | 2009 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bence Jones Protein; Calcium; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Monitoring, Physiologic; Multiple Myeloma; Patient Selection; Radiography; Thalidomide; Time; Treatment Outcome; Venous Thromboembolism | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Cluster Analysis; Dexamethasone; Endothelial Cells; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Stress, Physiological; Thalidomide; Venous Thromboembolism | 2013 |